Therapeutic potential of minor cannabinoids in psychiatric disorders: A systematic review.

Interest in cannabinoids' therapeutic potential in mental health is growing, supported by evidence of the involvement of the endocannabinoid system in psychiatric disorders such as anxiety, depression, and addiction. While the major cannabinoids cannabidiol (CBD) and Δ9-tetrahydrocannabinol (Δ9-THC) have been more extensively researched, approximately 120 minor cannabinoids from the cannabis plant have been identified. Although some displayed promising pharmacological profiles, research on their application for psychiatric disorders is fragmented. This systematic review evaluates, for the first time, both preclinical and clinical studies exploring minor cannabinoids' therapeutic potential in psychiatric disorders. 22 preclinical studies and one clinical study were included, investigating various minor cannabinoids in substance use disorders, anxiety disorders, depressive disorders, trauma and stressor-related disorders, psychotic disorders, neurodevelopmental disorders, and eating disorders. Despite the heterogeneous results and the moderate to high risk of bias in several articles, certain compounds demonstrate promise for further investigation. Δ8-tetrahydrocannabidivarin (Δ8-THCV) exhibited potential for nicotine addiction; Δ9-tetrahydrocannabidivarin (Δ9-THCV) for psychotic-like symptoms; cannabidiolic acid methyl ester (CBDA-ME) alleviated anxiety and depression-like symptoms, and cannabidivarin (CBDV) autism spectrum disorder-like symptoms.

• Publication year

  2024

• Venue

  European Neuropsychopharmacology

• Publication date

  2024-11-13

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.euroneuro.2024.10.006PMID 39541799
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of animal-to-human translation shows that only 5% of animal-tested therapeutic interventions obtain regulatory approval for human applications

  2024cited by this paper
• Anxiolytic effects of endocannabinoid enhancing compounds: A systematic review and meta-analysis.

  2023cited by this paper
• Toxicological Evaluation and Pain Assessment of Four Minor Cannabinoids Following 14-Day Oral Administration in Rats

  2023cited by this paper
• A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Δ8-Tetrahydrocannabivarin in Healthy Participants

  2023cited by this paper
• Cannabinoid Receptor 2 Blockade Prevents Anti-Depressive-like Effect of Cannabidiol Acid Methyl Ester in Female WKY Rats

  2023cited by this paper
• Pharmacokinetics of Oral Minor Cannabinoids in Blood and Brain

  2023cited by this paper
• Modulation of Endocannabinoid System Components in Depression: Pre-Clinical and Clinical Evidence

  2022cited by this paper
• Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses

  2022cited by this paper
• Autism and associated disorders: cannabis as a potential therapy.

  2022cited by this paper
• Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research

  2022cited by this paper
• Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses

  2021cited by this paper
• The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

  2021cited by this paper
• Cannabis in the management of PTSD: a systematic review

  2021cited by this paper
• Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials.

  2021cited by this paper
• The Cannabis Constituent Cannabigerol Does Not Disrupt Fear Memory Processes or Stress-Induced Anxiety in Mice

  2021cited by this paper
• Cannabis and cannabinoid use in autism spectrum disorder: a systematic review

  2021cited by this paper
• BEHAVIOURAL AND MOLECULAR EFFECTS OF CANNABIDIOLIC ACID IN MICE

  2020cited by this paper
• Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders

  2020cited by this paper
• In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa

  2020cited by this paper
• A time‐dependent contribution of hippocampal CB1, CB2 and PPARγ receptors to cannabidiol‐induced disruption of fear memory consolidation

  2020cited by this paper
• Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review

  2020cited by this paper
• Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice

  2020cited by this paper
• A systematic review of minor phytocannabinoids with promising neuroprotective potential

  2020cited by this paper
• Psychiatric Disorders and Cannabinoid Receptors.

  2020cited by this paper
• The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

  2019cited by this paper
• Endocannabinoid system involvement in autism spectrum disorder: An overview with potential therapeutic applications

  2019cited by this paper
• The critical importance of basic animal research for neuropsychiatric disorders

  2019cited by this paper
• Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.

  2019cited by this paper
• RoB 2: a revised tool for assessing risk of bias in randomised trials

  2019cited by this paper
• Δ8‐Tetrahydrocannabivarin has potent anti‐nicotine effects in several rodent models of nicotine dependence

  2019cited by this paper
• Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats

  2019cited by this paper
• Endocannabinoid System Components: Overview and Tissue Distribution.

  2019cited by this paper
• Acute oral cannabidiolic acid methyl ester reduces depression‐like behavior in two genetic animal models of depression

  2018cited by this paper
• Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System

  2018cited by this paper
• Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats

  2018cited by this paper
• Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials

  2018cited by this paper
• An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies

  2017cited by this paper
• Phytochemistry of Cannabis sativa L.

  2017cited by this paper
• Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB1 and CB2 receptors.

  2017cited by this paper
• Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads.

  2017cited by this paper
• The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models

  2017cited by this paper
• Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats

  2017cited by this paper
• Phytocannabinoids: a unified critical inventory.

  2016cited by this paper
• Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence

  2016cited by this paper
• Prohedonic Effect of Cannabidiol in a Rat Model of Depression

  2016cited by this paper
• The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial

  2016cited by this paper
• Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.

  2016cited by this paper
• Psychopharmacological Strategies in the Management of Posttraumatic Stress Disorder (PTSD): What Have We Learned?

  2015cited by this paper
• Neuromotor tolerability and behavioural characterisation of cannabidiolic acid, a phytocannabinoid with therapeutic potential for anticipatory nausea

  2015cited by this paper
• Cannabidiol as a Potential Treatment for Anxiety Disorders

  2015cited by this paper
• A systematic review of the antipsychotic properties of cannabidiol in humans.

  2015cited by this paper
• SYRCLE’s risk of bias tool for animal studies

  2014cited by this paper
• Effects of Phytocannabinoids on Anxiety, Mood, and the Endocrine System

  2014cited by this paper
• The phytocannabinoid, Δ9‐tetrahydrocannabivarin, can act through 5‐HT1A receptors to produce antipsychotic effects

  2014cited by this paper
• A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping

  2014cited by this paper
• Effect of chronic exposure to rimonabant and phytocannabinoids on anxiety-like behavior and saccharin palatability.

  2013cited by this paper
• Alterations in the endocannabinoid system in the rat valproic acid model of autism.

  2013cited by this paper
• Cannabidiolic acid prevents vomiting in Suncus murinus and nausea‐induced behaviour in rats by enhancing 5‐HT1A receptor activation

  2013cited by this paper
• Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature

  2012cited by this paper
• Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors

  2012cited by this paper
• On Disruption of Fear Memory by Reconsolidation Blockade: Evidence from Cannabidiol Treatment

  2012cited by this paper
• Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it.

  2012cited by this paper
• Endocannabinoid signaling and synaptic function.

  2012cited by this paper
• The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors

  2011cited by this paper
• Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L.

  2010cited by this paper
• Evidence that the plant cannabinoid cannabigerol is a highly potent α2‐adrenoceptor agonist and moderately potent 5HT1A receptor antagonist

  2010cited by this paper
• Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia.

  2010cited by this paper
• The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning

  2009cited by this paper
• Cannabis and psychiatric disorders: it is not only addiction

  2008cited by this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

  2008cited by this paper
• Models of schizophrenia in humans and animals based on inhibition of NMDA receptors.

  2008cited by this paper
• The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin

  2008cited by this paper
• Involvement of the endocannabinoid system in drug addiction.

  2006cited by this paper
• Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?

  2005cited by this paper
• Endocannabinoid System Modulates Relapse to Methamphetamine Seeking: Possible Mediation by the Arachidonic Acid Cascade

  2004cited by this paper
• The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

  2004cited by this paper
• Archaeological evidence for the tradition of psychoactive plant use In the old world

  2003cited by this paper
• Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.

  2001cited by this paper
• Autism

  1999cited by this paper
• The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol.

  1985cited by this paper
• Constituents of Cannabis sativa

  1979cited by this paper
• Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome.

  1978cited by this paper
• Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice

  1976cited by this paper
• Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats.

  1975cited by this paper
• Quasi morphine-abstinence syndrome

  1974cited by this paper
• The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish.

  1971cited by this paper
• Hashish. I. The structure of cannabidiol.

  1963cited by this paper
• Isolation of Cannabinol, Cannabidiol and Quebrachitol from Red Oil of Minnesota Wild Hemp

  1940cited by this paper

• Chronic suppression of monoacylglycerol lipase restores adult neurogenesis in the septal but not the temporal DG in Ts65Dn mouse model of Down syndrome.

  2026cites this paper
• Mapping the research landscape of minor cannabinoids: a bibliometric analysis of research trends and hotspots.

  2026cites this paper
• Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades.

  2026cites this paper
• Enhancing data compatibility in an evolving landscape: Medical cannabis and polysubstance use protocols in the PhenX Toolkit.

  2025cites this paper
• Cannabinoids for Anxiety and Sleep Disturbances: A Scoping Review

  2025cites this paper
• Resurrected Ancestral Cannabis Enzymes Unveil the Origin and Functional Evolution of Cannabinoid Synthases.

  2025cites this paper
• A Systematic Review of Traditional Uses, Phytochemistry, and Pharmacology of Chinese Herb Medicine for Schizophrenia

  2025cites this paper
• Advances in Extraction and Quantification of Minor Phytocannabinoids

  2025cites this paper